Associated tags: Patient, Pharmaceutical industry, Isavuconazonium, Infection, Research, Mycosis, Communication, SIX Swiss Exchange, CHF, LR
Locations: ALLSCHWIL, CH
The funding will support an ongoing Basilea research program to develop an antibiotic from a novel class for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.\nThe program aims to develop selective small-molecule inhibitors of DXR, an enzyme in the bacterial isoprenoid biosynthesis pathway.
Key Points:
- The funding will support an ongoing Basilea research program to develop an antibiotic from a novel class for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.\nThe program aims to develop selective small-molecule inhibitors of DXR, an enzyme in the bacterial isoprenoid biosynthesis pathway.
- Laurenz Kellenberger, Chief Scientific Officer, said: \xe2\x80\x9cThe medical problem of antimicrobial resistance keeps increasing.
- Therefore, new antibiotics are urgently needed that will be able to address resistance that is growing against current treatment options.
- We are delighted to be partnering with CARB-X for the development of truly innovative antibiotics directed against this unexploited bacterial target.
Retrieved on:
Wednesday, April 21, 2021
Accordingly, shareholders exercised their voting rights exclusively via the independent proxy.
Key Points:
- Accordingly, shareholders exercised their voting rights exclusively via the independent proxy.
- In addition, Dr. Nicklasson and Dr. Werner were re-elected and Dr. Onetto was newly elected to the compensation committee.
- We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases.
- Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.\n'
Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced the successful closing of the previously announced divestment of its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (BPC) to the U.S.-based custom manufacturing organization PHTInternationalInc.
Key Points:
- Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced the successful closing of the previously announced divestment of its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (BPC) to the U.S.-based custom manufacturing organization PHTInternationalInc.
- Basilea has received the initial payment of USD2.5 million and is entitled to receive additional payments of USD3.8 million over the course of the next three years.
- PHT continues to provide R&D services to Basilea through the existing site in China.
- Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland.
Retrieved on:
Wednesday, March 24, 2021
The interim analysis of cohort 2 is based on 14 evaluable patients who had at least one post-baseline tumor assessment.
Key Points:
- The interim analysis of cohort 2 is based on 14 evaluable patients who had at least one post-baseline tumor assessment.
- The positive interim analysis allows the study to advance to its next stage and enrol a total of 43 patients.
- Dr. Marc Engelhardt, Chief Medical Officer, said: We are very pleased with the positive interim results for this cohort of iCCA patients with FGFR2 gene mutations or amplifications.
- The clinical benefit with derazantinib is similar to that reported for iCCA patients with FGFR2 gene fusions earlier this year.
Retrieved on:
Tuesday, February 16, 2021
The achievements in 2020 include launches in key markets in Asia Pacific and the approval in Russia.
Key Points:
- The achievements in 2020 include launches in key markets in Asia Pacific and the approval in Russia.
- We therefore remain confident that our partners will have launched Cresemba in 60 countries by the end of 2021.
- In 2020, our partner CR Gosun obtained regulatory approval for Zevtera in China, which triggered a milestone payment of CHF 3 million to Basilea.
- We are therefore looking forward to interim results from this second cohort of FIDES-01, which are expected for H1 2021.
Retrieved on:
Monday, February 15, 2021
All 72 employees and the facilities will be transferred to PHT.
Key Points:
- All 72 employees and the facilities will be transferred to PHT.
- Basilea is entitled to additional payments of USD3.8million over the course of the next three years, for a total purchase price of USD 6.3 million.
- Importantly, PHT has committed to maintaining R&D services through the existing site in China to Basilea.
- PHT International Inc. is a privately owned custom manufacturing organization for chemicals for the pharmaceutical industry and other sectors.
Retrieved on:
Friday, February 12, 2021
Branches of biology,
Clinical medicine,
Medicine,
Breakthrough therapy,
Orphan drugs,
Cancer immunotherapy,
Immune system,
Clusters of differentiation,
Atezolizumab,
Checkpoint inhibitor,
Colony stimulating factor 1 receptor,
Macrophage colony-stimulating factor The combination of derazantinib and atezolizumab is supported by preclinical data demonstrating derazantinibs strong inhibition of colony-stimulating-factor-1-receptor kinase (CSF1R).
Key Points:
- The combination of derazantinib and atezolizumab is supported by preclinical data demonstrating derazantinibs strong inhibition of colony-stimulating-factor-1-receptor kinase (CSF1R).
- CSF1R inhibition may revert tumor-induced immunosuppression and thereby enhance the response to immune-checkpoint inhibition.
- The following e-poster was presented at ASCO GU 2021:
Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02.
- The first study, FIDES-01, is a registrational phase 2 study in patients with inoperable or advanced iCCA.
Retrieved on:
Thursday, February 11, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has promoted a potential first-in-class small-molecule kinase inhibitor from its research portfolio into the next preclinical development stage, which triggers an undisclosed milestone payment to its external partner.
Key Points:
- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has promoted a potential first-in-class small-molecule kinase inhibitor from its research portfolio into the next preclinical development stage, which triggers an undisclosed milestone payment to its external partner.
- Basilea is planning to start preclinical studies with the goal of filing for an IND, i.e.
- Dr. Laurenz Kellenberger, Chief Scientific Officer, said: We are pleased with reaching this important preclinical milestone in our external collaboration.
- We look forward to achieving the next important milestone in this program, which will be the initiation of clinical studies with this potential first-in-class kinase inhibitor within the next twelve months.
Retrieved on:
Wednesday, February 10, 2021
Enrolment into cohort 2 of FIDES-01 is ongoing, assessing the activity of derazantinib in iCCA patients with FGFR2 gene mutations or amplifications.
Key Points:
- Enrolment into cohort 2 of FIDES-01 is ongoing, assessing the activity of derazantinib in iCCA patients with FGFR2 gene mutations or amplifications.
- The disease control rate (DCR), reflecting the proportion of patients with a partial response or with stable disease, was 72.8%.
- The results are not yet fully mature, as 12 patients are still ongoing, including 3 patients with a partial response.
- The first study, FIDES-01, is a phase 2 study in patients with inoperable or advanced iCCA.
Retrieved on:
Tuesday, February 9, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of the antifungal Cresemba (isavuconazole) by Pfizer in Europe and Israel exceeded the threshold triggering a milestone payment to Basilea of USD 10 million.
Key Points:
- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of the antifungal Cresemba (isavuconazole) by Pfizer in Europe and Israel exceeded the threshold triggering a milestone payment to Basilea of USD 10 million.
- Basilea is entitled to receive milestone payments upon Pfizers cumulative Cresemba sales in Pfizers licensed territories exceeding certain thresholds.
- Under the agreement, sales milestones totaling USD 12 million were triggered in 2019 and regulatory and commercial milestones totaling around USD 6 million were triggered in 2020.
- David Veitch, Chief Executive Officer of Basilea, said: We are very pleased that the continued strong sales performance of Cresemba has now triggered the 10 million US dollar milestone from Pfizer.
